Shares of Emergent Biosolutions Inc (NYSE:EBS) have earned an average rating of “Hold” from the nine ratings firms that are currently covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $61.86.

Several research analysts recently commented on the stock. Cantor Fitzgerald set a $68.00 price objective on shares of Emergent Biosolutions and gave the stock a “buy” rating in a report on Tuesday, September 11th. Argus raised their price objective on shares of Emergent Biosolutions to $70.00 and gave the stock an “average” rating in a report on Tuesday, September 11th. They noted that the move was a valuation call. Chardan Capital raised their price objective on shares of Emergent Biosolutions from $60.00 to $66.00 and gave the stock a “buy” rating in a report on Tuesday, September 4th. Cowen reaffirmed a “hold” rating and issued a $49.00 price objective on shares of Emergent Biosolutions in a report on Wednesday, August 29th. Finally, Wells Fargo & Co set a $65.00 price objective on shares of Emergent Biosolutions and gave the stock a “hold” rating in a report on Wednesday, August 29th.

EBS traded down $0.07 on Wednesday, hitting $60.73. The company’s stock had a trading volume of 5,309 shares, compared to its average volume of 343,086. The company has a market cap of $3.29 billion, a PE ratio of 31.87, a price-to-earnings-growth ratio of 1.40 and a beta of 1.23. Emergent Biosolutions has a 12 month low of $36.38 and a 12 month high of $67.24. The company has a current ratio of 5.59, a quick ratio of 4.15 and a debt-to-equity ratio of 0.01.

Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported $1.07 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.88 by $0.19. The company had revenue of $220.20 million during the quarter, compared to the consensus estimate of $208.94 million. Emergent Biosolutions had a net margin of 16.55% and a return on equity of 15.09%. Emergent Biosolutions’s revenue for the quarter was up 118.5% on a year-over-year basis. During the same period last year, the firm earned $0.13 EPS. Research analysts forecast that Emergent Biosolutions will post 2.35 earnings per share for the current fiscal year.

In other Emergent Biosolutions news, Chairman Fuad El-Hibri sold 36,318 shares of the firm’s stock in a transaction on Tuesday, August 14th. The shares were sold at an average price of $55.98, for a total value of $2,033,081.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ronald Richard sold 7,893 shares of the firm’s stock in a transaction on Tuesday, August 21st. The shares were sold at an average price of $60.02, for a total transaction of $473,737.86. Following the completion of the transaction, the director now directly owns 21,063 shares of the company’s stock, valued at $1,264,201.26. The disclosure for this sale can be found here. Over the last three months, insiders sold 164,626 shares of company stock valued at $9,895,754. Insiders own 13.40% of the company’s stock.

A number of large investors have recently made changes to their positions in the business. Summit Trail Advisors LLC raised its position in shares of Emergent Biosolutions by 4,093.4% during the 1st quarter. Summit Trail Advisors LLC now owns 1,378,959 shares of the biopharmaceutical company’s stock valued at $1,379,000 after buying an additional 1,346,075 shares in the last quarter. BlackRock Inc. raised its position in shares of Emergent Biosolutions by 20.2% during the 2nd quarter. BlackRock Inc. now owns 5,372,711 shares of the biopharmaceutical company’s stock valued at $271,268,000 after buying an additional 901,882 shares in the last quarter. Millennium Management LLC raised its position in shares of Emergent Biosolutions by 29.6% during the 1st quarter. Millennium Management LLC now owns 917,065 shares of the biopharmaceutical company’s stock valued at $48,283,000 after buying an additional 209,581 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Emergent Biosolutions by 10.6% during the 2nd quarter. Renaissance Technologies LLC now owns 2,066,511 shares of the biopharmaceutical company’s stock valued at $104,338,000 after buying an additional 198,600 shares in the last quarter. Finally, FMR LLC raised its position in shares of Emergent Biosolutions by 192.7% during the 2nd quarter. FMR LLC now owns 290,507 shares of the biopharmaceutical company’s stock valued at $14,668,000 after buying an additional 191,248 shares in the last quarter. 83.00% of the stock is owned by hedge funds and other institutional investors.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.

Featured Story: Call Option

Analyst Recommendations for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.